Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that the United States Food and ...

Immutep (NASDAQ:IMMP) shares jumped sharply on Wednesday after the company announced that the U.S. Food and Drug ...

Funding will enable progress on the ADCE-T02 Phase I Tiffany-01 cohort expansion in a range of solid tumours.

Storm Therapeutics raises $56M in Series C funding to accelerate cancer therapy development and expand its innovative ...

Angiosarcoma is an aggressive malignancy derived from endothelial cells, characterised by its rapid progression, heterogeneity and distinct clinical challenges. As a subset of soft tissue sarcomas, ...

Immutep (IMM) stock soared 101% after FDA granted Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma. Market exclusivity & tax benefits await.

Although relatively rare, soft tissue sarcoma after breast cancer treatment was linked most strongly to treatment with radiation, according to data from two large U.S. cohorts of breast cancer ...

Soft tissue sarcomas---rare tumours of the connective tissue---should be treated at the few centres which see most cases, in order to give patients the best chance of good outcomes, concludes an ...

Soft tissue sarcomas are rare solid tumors that are being increasingly classified and treated by subtype. Approximately 12,020 people will be diagnosed with a soft tissue sarcoma in the United States ...

Investigators from Cedars-Sinai Cancer have discovered that cancerous tumors called soft-tissue sarcomas produce a protein that switches immune cells from tumor-attacking to tumor-promoting. The study ...

FDA orphan drug designation provides incentives including regulatory support, tax credits, fee exemptions, and seven years of ...